Increased incidence of euthyroid and hyperthyroid goiters independently of thyrotropin in patients with acromegaly.
The incidence of palpable goiters, the thyroid functional state and thyroid radioisotope uptake was analyzed retrospectively in 80 patients with acromegaly and 80 patients with prolactinomas. 71% of all patients with acromegaly had an enlargement of the thyroid (goiter); 49% of them had diffuse and 39% nodular goiters. The incidence of goiters in patients with prolactinomas from the same iodine deficient geographic region was only 35% (82% diffuse and 18% nodular). 17.5% of acromegalic patients underwent thyroid surgery before diagnosis of growth hormone excess. 17.5% of acromegalic patients with goiters had autonomous areas in their thyroids and 5% were clearly hyperthyroid. Goiters developed slightly more often in females (74%) than in males (67%). The mean preoperative growth hormone level was higher in acromegalic patients with goiter. The incidence of goiters was positively correlated with the documented time of elevated growth hormone concentration in serum. Two patients with exaggerated response of thyrotropin (TSH) (delta TSH greater than 20 mU/l) to the application of thyrotropin-releasing hormone (TRH) had no goiters. On the other hand most patients (61%) with goiters had a low TSH-response to TRH (delta TSH less than 10 mU/l) representing in part occult autonomy of thyroid function. No patient with prolactinoma has had previous thyroid surgery nor thyroid autonomy. One patient with prolactinoma suffered from Graves' disease and none of the acromegalic patients had this disease. We finally conclude that the elevation of growth hormone leads to increased incidence of euthyroid and hyperthyroid (autonomous) goiters independently of the influence of TSH.
Wüster
C
C
Abteilung Innere Medizin I, Ruprecht-Karls-Universität, Heidelberg, Germany.
Steger
G
G
Schmelzle
A
A
Gottswinter
J
J
Minne
H W
HW
Ziegler
R
R
D000172:Acromegaly / Q000150:complications*; D000328:Adult; D005260:Female; D006042:Goiter / Q000150:complications* / Q000453:epidemiology; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006980:Hyperthyroidism / Q000150:complications* / Q000453:epidemiology; D015994:Incidence; D008297:Male; D010911:Pituitary Neoplasms / Q000150:complications*; D015175:Prolactinoma / Q000150:complications*; D012727:Sex Characteristics; D013972:Thyrotropin / Q000097:blood / Q000378:metabolism*; D013973:Thyrotropin-Releasing Hormone
D013973:Thyrotropin-Releasing Hormone; D013972:Thyrotropin; D013006:Growth Hormone